SLC5A2 and type 2 diabetes mellitus: A recent study conducted in primary care found that 44% of patients with Type-2 diabetes had the coronary syndrome, heart failure, and kidney disease.18 Another interesting study showed that 27.7% of patients with Type-2 diabetes had undiagnosed heart failure.19 The current results imply that nearly half of patients with Type-2 diabetes qualify for treatments with SGLT-2 inhibitors.